Download presentation
Presentation is loading. Please wait.
Published byAspen Burditt Modified over 9 years ago
1
Veterinary Drug Compounding – A Drug Sponsor’s Perspective AAVPT 14 th Biennial Symposium, May 16-17, 2005, Rockville, MD Pg. 205-214 (Slide #1-10)
2
May 17, 2005 Julie Spagnoli, MS Director, Federal Government Affairs Bayer HealthCare, LLC Animal Health Division 1275 Pennsylvania Ave., N.W. Washington, D.C. 20004 Telephone: (202) 765-3775 E-mail: Julie.Spagnoli.B@Bayer.com
3
May 17, 2005 Veterinary Drug Compounding Concerns Sponsors of pioneer drugs cannot offer for sale bulk active ingredients as an approved drug for compounding Bulk active ingredients offered come from other sources and likely do not meet sponsor’s specifications Compounded products may not meet safety or efficacy requirements of approved products
4
May 17, 2005 Veterinary Drug Compounding Concerns Since 2000, Bayer has notified CVM of numerous violations by pharmacies and of suppliers of unapproved bulk active ingredients For most, no action was taken Finally, a civil suit was filed by Bayer against one of the most egregious offenders
6
May 17, 2005 Veterinary Drug Compounding: Tabor Case In May 2000, a Bayer representative purchased a compounded product sold as enrofloxacin injectable solution from Tabor Drug. Drug and analytical results showing it to be counterfeit material were sent to CVM In 2002, Bayer notified CVM of additional counterfeit material being offered by an associated business, Kalchem International
7
May 17, 2005 Veterinary Drug Compounding: Tabor Case In 2003, Bayer again notified CVM of the illegal enrofloxacin being offered for sale, including a recommended withdrawal period for swine. Bayer has been pursuing swine use for Baytril, but it is not yet approved. In July 2003, Bayer filed suit against Tabor and Kalchem for deceptive trade practices for offering for sale a drug product posing as an equivalent to Baytril 100 injectable solution Bayer is the only legitimate source of this product or enrofloxacin
8
May 17, 2005 Veterinary Drug Compounding: Tabor Case Kalchem purchased a total of 1,305 kg of counterfeit enrofloxacin from four different sources Kalchem also sold 68.15 Kg to other pharmacies Most material was enrofloxacin HCl - Bayer’s approved products are manufactured with enrofloxacin base
9
May 17, 2005 Veterinary Drug Compounding: Tabor Case Tabor purchased at least 364.86 Kg enrofloxacin from Kalchem and manufactured 6,574 bottles of counterfeit 100mg/ml injectable Approximately 109,500 doses of counterfeit product sold to and administered by veterinarians and livestock producers
10
May 17, 2005 Illegal Veterinary Drug Compounding: Threats to food safety and animal health Counterfeit bulk active ingredients from China or other countries, are not from approved sources and could be contaminated, misrepresented or ineffective Unapproved drug substances may pose a threat to animal health and food safety, if used in food animals Stronger controls are needed by FDA and U.S. Customs to stop the importation of these illegal drug substances
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.